Occupational Laboratory Exposures to Burkholderia pseudomallei in the United States: A Review of Exposures and Serological Monitoring Data, 2008–2024
Authors:
- Brian T. RichardsonBRBrian T. Richardson
- Mindy G. ElrodMEMindy G. Elrod
- Katherine M. DeBordKDKatherine M. DeBord
- Caroline A. SchrodtCSCaroline A. Schrodt
- Julie M. ThompsonJTJulie M. Thompson
- Tina J. BenoitTBTina J. Benoit
- Lindy LiuLLLindy Liu
- Julia K. PetrasJPJulia K. Petras
- David BlaneyDBDavid Blaney
- Jay E. GeeJGJay E. Gee
- Vit KraushaarVKVit Kraushaar
- Danielle StanekDSDanielle Stanek
Open Access
Abstract
Infection with Burkholderia pseudomallei, the causative agent of melioidosis, is uncommon in the United States (U.S.), leading to delays in pathogen identification and clinical diagnosis which can often lead to laboratory exposures. The indirect hemagglutination assay (IHA) is the primary serological test for confirming exposure to B. pseudomallei. In the U.S., a titer of ≥1:40 suggests exposure to B. pseudomallei or a closely related species, and a 4-fold rise in IHA titer ≥1:40 with clinically compatible illness is considered diagnostically probable. A retrospective analysis of 160 voluntarily reported laboratory exposure events to B. pseudomallei across 29 U.S. jurisdictions and 5 countries between 2008–2024 was conducted. This analysis included post-exposure management data and IHA results for 855 exposed laboratory personnel who had serological monitoring performed at the U.S. Centers for Disease Control and Prevention (CDC). Among exposed laboratory personnel, 105 (12%) had a seropositive titer. Of these, ninety-one (87%) laboratory personnel remained seropositive (≥1:40) at their last IHA test. Five (1%) people had a 4-fold rise in titers, though none developed melioidosis. This report underscores the need for prospective studies to evaluate seropositive laboratory personnel and to update risk guidance for laboratory exposures in non-endemic areas.Keywords
Funding Information
- Centers for Disease Control and Prevention Emerging Infectious Disease funds
This publication has 40 references indexed in Scilit:
- Seroprevalence of melioidosis and its associated risk factors –A population-based study in Odisha, Eastern IndiaCurrent Research in Microbial Sciences, 2025
- The Darwin Prospective Melioidosis Study: a 30-year prospective, observational investigationThe Lancet Infectious Diseases, 2021
- Systematic review and meta-analysis of diagnostic tests for diagnosis of melioidosisActa Tropica, 2021
- Global burden of melioidosis in 2015: a systematic review and data synthesisThe Lancet Infectious Diseases, 2019
- Seroepidemiological surveillance of Burkholderia pseudomallei in BangladeshTransactions of the Royal Society of Tropical Medicine and Hygiene, 2012
- Validation and comparison of an extrapolysaccharide (EPS)-based in-house ELISA and the PanBio melioidosis rapid cassette test-kits for serodiagnosis of melioidosis in a non-endemic areaTransactions of the Royal Society of Tropical Medicine and Hygiene, 2008
- Prospective evaluation of a rapid immunochromogenic cassette test for the diagnosis of melioidosis in northeast ThailandTransactions of the Royal Society of Tropical Medicine and Hygiene, 2006
- Melioidosis as an emerging global problemActa Tropica, 2000
- Melioidosis and safety in the clinical laboratoryJournal of Hospital Infection, 1992
- Laboratory acquired melioidosisThe American Journal of Medicine, 1968